Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
2.

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625. doi: 10.1016/j.bbrc.2018.04.120. Epub 2018 Apr 30.

PMID:
29679564
3.

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J.

Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8.

PMID:
28668277
4.

Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.

Shahabi A, Lewinger JP, Ren J, April C, Sherrod AE, Hacia JG, Daneshmand S, Gill I, Pinski JK, Fan JB, Stern MC.

Prostate. 2016 Oct;76(14):1239-56. doi: 10.1002/pros.23211. Epub 2016 Jun 8.

PMID:
27272349
5.

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI.

Clin Genitourin Cancer. 2016 Oct;14(5):450-456.e1. doi: 10.1016/j.clgc.2016.01.013. Epub 2016 Feb 6.

PMID:
26935231
6.

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E17-22. doi: 10.5489/cuaj.3163. Epub 2016 Jan 14.

7.

Platelet-rich plasma increases transforming growth factor-beta1 expression at graft-host interface following autologous osteochondral transplantation in a rabbit model.

Boakye LA, Ross KA, Pinski JM, Smyth NA, Haleem AM, Hannon CP, Fortier LA, Kennedy JG.

World J Orthop. 2015 Dec 18;6(11):961-9. doi: 10.5312/wjo.v6.i11.961. eCollection 2015 Dec 18.

8.

Low Level of Evidence and Methodologic Quality of Clinical Outcome Studies on Cartilage Repair of the Ankle.

Pinski JM, Boakye LA, Murawski CD, Hannon CP, Ross KA, Kennedy JG.

Arthroscopy. 2016 Jan;32(1):214-22.e1. doi: 10.1016/j.arthro.2015.06.050. Epub 2015 Sep 11. Review.

PMID:
26372522
9.

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME.

PLoS One. 2015 Feb 18;10(2):e0117758. doi: 10.1371/journal.pone.0117758. eCollection 2015.

10.

Effects of luteinizing hormone receptor signaling in prostate cancer cells.

Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J.

Prostate. 2015 Feb;75(2):141-50. doi: 10.1002/pros.22899. Epub 2014 Nov 12.

PMID:
25393079
11.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.

12.

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23.

13.

Formation of covalently bonded polycyclic hydrocarbon ions by intracluster polymerization of ionized ethynylbenzene clusters.

Momoh PO, Attah IK, El-Shall MS, Kanters RP, Pinski JM, Abrash SA.

J Phys Chem A. 2014 Sep 18;118(37):8251-63. doi: 10.1021/jp5010488. Epub 2014 Apr 17.

PMID:
24689826
14.

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.

Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B.

Cancer Res. 2014 May 15;74(10):2857-68. doi: 10.1158/0008-5472.CAN-13-2003. Epub 2014 Mar 19.

15.

LHRH and LHR genotypes and prostate cancer incidence and survival.

Ingles SA, Liu SV, Pinski J.

Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):228-34. eCollection 2013.

16.

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB.

Urology. 2014 Jan;83(1):159-65. doi: 10.1016/j.urology.2013.08.074. Epub 2013 Nov 12. Erratum in: Urology. 2014 Jun;83(6):1446.

PMID:
24238569
17.

The ability of Sos1 to oligomerize the adaptor protein LAT is separable from its guanine nucleotide exchange activity in vivo.

Kortum RL, Balagopalan L, Alexander CP, Garcia J, Pinski JM, Merrill RK, Nguyen PH, Li W, Agarwal I, Akpan IO, Sommers CL, Samelson LE.

Sci Signal. 2013 Nov 12;6(301):ra99. doi: 10.1126/scisignal.2004494.

18.

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK.

Clin Genitourin Cancer. 2013 Dec;11(4):416-22. doi: 10.1016/j.clgc.2013.07.011. Epub 2013 Oct 4.

PMID:
24099865
19.

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI.

J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19.

20.

A phospholipase C-γ1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice.

Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.

J Immunol. 2013 Jan 1;190(1):147-58. doi: 10.4049/jimmunol.1201458. Epub 2012 Dec 3.

21.

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI.

Clin Nucl Med. 2012 Jul;37(7):637-43. doi: 10.1097/RLU.0b013e318252d829.

22.

Deconstructing Ras signaling in the thymus.

Kortum RL, Sommers CL, Pinski JM, Alexander CP, Merrill RK, Li W, Love PE, Samelson LE.

Mol Cell Biol. 2012 Jul;32(14):2748-59. doi: 10.1128/MCB.00317-12. Epub 2012 May 14.

23.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
24.

Immune response to sipuleucel-T in prostate cancer.

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI.

Cancers (Basel). 2012 Apr 18;4(2):420-41. doi: 10.3390/cancers4020420.

25.

Ethnic differences in neuroendocrine expression in prostate cancer tissue.

Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J.

Anticancer Res. 2011 Nov;31(11):3897-901.

PMID:
22110216
26.

Targeted Sos1 deletion reveals its critical role in early T-cell development.

Kortum RL, Sommers CL, Alexander CP, Pinski JM, Li W, Grinberg A, Lee J, Love PE, Samelson LE.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12407-12. doi: 10.1073/pnas.1104295108. Epub 2011 Jul 11.

27.

Advanced prostate cancer: new agents, new questions.

Dorff TB, Pinski J.

Oncology (Williston Park). 2011 May;25(6):509, 512. No abstract available.

28.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
29.

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV.

Prostate. 2011 Jun 1;71(8):892-8. doi: 10.1002/pros.21305. Epub 2010 Nov 17.

PMID:
21456071
30.

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.

Liu SV, Liu S, Pinski J.

Expert Opin Investig Drugs. 2011 Jun;20(6):769-78. doi: 10.1517/13543784.2011.574611. Epub 2011 Mar 31. Review.

PMID:
21449823
31.

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

Schally AV, Engel JB, Emons G, Block NL, Pinski J.

Curr Drug Deliv. 2011 Jan;8(1):11-25. Review.

PMID:
21034424
32.

Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.

Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J.

Clin Cancer Res. 2010 Sep 15;16(18):4675-80. doi: 10.1158/1078-0432.CCR-10-1113. Epub 2010 Jul 29.

33.

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.

Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J.

Prostate. 2010 Sep 1;70(12):1359-70. doi: 10.1002/pros.21173.

PMID:
20623636
34.

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2010 Nov 1;70(15):1692-700. doi: 10.1002/pros.21204.

PMID:
20564320
35.

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH.

Clin Cancer Res. 2010 Jun 1;16(11):3028-34. doi: 10.1158/1078-0432.CCR-09-3122. Epub 2010 May 18.

36.

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.

Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA.

Am J Clin Oncol. 2011 Feb;34(1):27-31. doi: 10.1097/COC.0b013e3181cae766.

PMID:
20142723
37.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR.

Clin Genitourin Cancer. 2009 Jan;7(1):43-50. doi: 10.3816/CGC.2009.n.008.

PMID:
19213668
38.

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.

Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2009 Jan 1;69(1):12-23. doi: 10.1002/pros.20851.

PMID:
18814146
39.

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW.

BJU Int. 2008 Dec;102(11):1601-6. doi: 10.1111/j.1464-410X.2008.08017.x. Epub 2008 Sep 8.

40.

Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer.

Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV.

Prostate. 2008 Oct 1;68(14):1555-60. doi: 10.1002/pros.20815.

PMID:
18651557
41.

Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.

Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK.

Anticancer Res. 2008 Jan-Feb;28(1B):425-30.

42.

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN Jr.

Clin Genitourin Cancer. 2007 Dec;5(7):433-7. doi: 10.3816/CGC.2007.n.031.

PMID:
18272025
43.

Diet and prostate cancer risk reduction.

Cheung E, Wadhera P, Dorff T, Pinski J.

Expert Rev Anticancer Ther. 2008 Jan;8(1):43-50. Review.

PMID:
18095882
44.

Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.

Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J.

Hum Pathol. 2007 Oct;38(10):1547-52. Epub 2007 Jul 19.

PMID:
17640713
45.

Evolving treatment paradigms for locally advanced and metastatic prostate cancer.

Dorff TB, Quek ML, Daneshmand S, Pinski J.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1639-51. Review.

PMID:
17134367
46.

Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.

Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski JK, Stanczyk FZ, Jones PA, Coetzee GA.

Mol Cell Biol. 2006 Oct;26(19):7331-41.

47.

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J.

Urology. 2006 Jun;67(6):1247-52. Epub 2006 May 12.

PMID:
16697447
48.

Genistein-induced neuroendocrine differentiation of prostate cancer cells.

Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV.

Prostate. 2006 Aug 1;66(11):1136-43.

PMID:
16652383
49.

Postchemotherapy residual masses in advanced seminoma: current management and outcomes.

Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG.

Expert Rev Anticancer Ther. 2005 Oct;5(5):869-74. Review.

PMID:
16221056
50.

Glucose metabolism of human prostate cancer mouse xenografts.

Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS.

Mol Imaging. 2005 Apr-Jun;4(2):91-7.

PMID:
16105512

Supplemental Content

Loading ...
Support Center